Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 5, 2008, Pages 2148-2155

  Phillips, M Joe ^a,b   Walker, Tiffany A ^a   Choi, Hee Young ^a,c   Faulkner, Amanda E ^a   Kim, Moon K ^a   Sidney, Sheree S ^b   Boyd, Amber P ^b   Nickerson, John M ^b   Boatright, Jeffrey H ^b   Pardue, Machelle T ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

TAUROURSODEOXYCHOLIC ACID; CHOLAGOGUE; OPSIN; TAUROCHENODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; C57BL MOUSE; CELL COUNT; CONTROLLED STUDY; CORNEA PRESERVATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; LIGHT ADAPTATION; MOUSE; MOUSE STRAIN; NICK END LABELING; NONHUMAN; PERINATAL PERIOD; PHOTORECEPTOR MEMBRANE; PRIORITY JOURNAL; RD 10 MOUSE; RETINA CONE; RETINA ROD; RETINITIS PIGMENTOSA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE; ANIMAL; CELL NUCLEUS; DARK ADAPTATION; DISEASE MODEL; DRUG EFFECT; FEMALE; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOTORECEPTOR; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL COUNT; CELL NUCLEUS; CHOLAGOGUES AND CHOLERETICS; DARK ADAPTATION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; OPSIN; PHOTORECEPTORS, VERTEBRATE; RETINITIS PIGMENTOSA; TAUROCHENODEOXYCHOLIC ACID;

EID: 44649159782     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1012     Document Type: Article

References (41)

1. Berson EL. Retinitis pigmentosa: unfolding its mystery. Proc Natl AcadSciUSA. 1996;93:4526-4528.
2. Reme CE, Grimm C, Hafezi F, Marti A, Wenzel A. Apoptotic cell death in retinal degenerations. Prog Retin Eye Res. 1998;17:443-464.
3. Cidian ZYD. Dictionary of Traditional Chinese Medicine. Shanghai: Shanghai Sci and Technology Press; 2004.
4. Williamson DF, Phipps MJ. Proceedings in the Third Annual Symposium on the Trade in Bear Parts 1999. Hong Kong: TRAFFIC East Asia; 2001.
5. Hofmann AF. Medical treatment of cholesterol gallstones by bile desaturating agents. Hepatology. 1984;4(suppl):199S-208S.
6. Crosignani A, Battezzati PM, Setchell KD, et al. Tauroursodeoxy- cholic acid for treatment of primary biliary cirrhosis: a dose-response study. Dig Dis Sci. 1996;41:809-815.
7. Schoemaker MH, Gommans WM, Conde de la Rosa L, et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol. 2003;39:153-161.
8. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad SciUSA. 2002;99:10671-10676.
9. Keene CD, Rodrigues CM, Eich T, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. ExpNeu- rol. 2001;171:351-360.
10. Duan WM, Rodrigues CM, Zhao LR, Steer CJ, Low WC. Taurour- sodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant. 2002;11:195-205.
11. Rodrigues CM, Sola S, Nan Z, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad SciUSA. 2003;100:6087-6092.
12. Rodrigues CM, Spellman SR, Sola S, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab. 2002;22:463-471.
13. Castro RE, Amaral JD, Sola S, Kren BT, Steer CJ, Rodrigues CM. Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes. Am J Physiol. 2007;293:G327-G334.
14. Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamateinduced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004;311:845-852.
15. Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neuro- chem. 2006;98:1610-1618.
16. Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. JNeurochem. 2004;90:567-575.
17. Sola S, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF- /31-induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry. 2004;43:8429-8438.
18. Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursode- oxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9:226-234.
19. Beuers U, Denk GU, Soroka CJ, et al. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J Biol Chem. 2003;278:17810-17818.
20. +-dependent cyto- protective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol. 2006;168:398-409.
21. Dent P, Fang Y, Gupta S, et al. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology. 2005;42: 1291-1299.
22. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998;4:165-178.
23. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ. 1999;6:842-854.
24. Colell A, Coll O, Garcia-Ruiz C, et al. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathi-one. Hepatology. 2001;34:964-971.
25. Boatright JH, Moring AG, McElroy C, et al. Tool from ancient pharmacopoeia prevents vision loss. MolVis. 2006;12:1706-1714.
26. Chang B, Hawes NL, Pardue MT, et al. Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. Vis Res. 2007;47:624-633.
27. Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heck- enlively JR. Retinal degeneration mutants in the mouse. Vis Res. 2002;42:517-525.
28. Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature. 1990;347: 677- 680.
29. Pittler SJ, Baehr W. Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc Natl Acad SciUSA. 1991;88:8322-8326.
30. Gargini C, Terzibasi E, Mazzoni F, Strettoi E. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. JCompNeurol. 2007;500:222-238.
31. Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106:1780-1785.
32. Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ur- sodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol. 2001;96:3152-3157.
33. Pardue MT, Phillips MJ, Yin H, et al. Neuroprotective effect of subretinal implants in the RCS rat. Invest Ophthalmol Vis Sci. 2005;46:674-682.
34. Pardue MT, Phillips MJ, Yin H, et al. Possible sources of neuropro- tection following subretinal silicon chip implantation in RCS rats. J Neural Eng. 2005;2:S39-S47.
35. Carter-Dawson LD, LaVail MM. Rods and cones in the mouse retina, I: structural analysis using light and electron microscopy. J Comp Neurol. 1979;188:245-262.
36. Daniele LL, Lillo C, Lyubarsky AL, et al. Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the Nrl knockout mouse. Invest Ophthalmol Vis Sci. 2005;46: 2156-2167.
37. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med. 2006;3:e347.
38. -/- mice: a defect that can be corrected by 11-cis retinal. Invest Ophthalmol Vis Sci. 2005;46:3876-3882.
39. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxy- cholic acid-adverse effects and drug interactions. Alimentary Pharmacol Therapeut. 2003;18:963-972.
40. Wright AF, Jacobson SG, Cideciyan AV, et al. Lifespan and mito- chondrial control of neurodegeneration. Nat Genet. 2004;36: 1153-1158.
41. Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res. 2007; 85:7-14.